NK4 gene expression enhances 5-fluorouracil-induced apoptosis of murine colon cancer cells

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2217-2224

  Taiyoh, Hiroaki ^a   Kubota, Takeshi ^a   Fujiwara, Hitoshi ^a   Matsumura, Atsushi ^a   Murayama, Yasutoshi ^a   Okamoto, Kazuma ^a   Ichikawa, Daisuke ^a   Ochiai, Toshiya ^a   Nakamura, Takahiro ^b   Matsumoto, Kunio ^b   Nakamura, Toshikazu ^c   Otsuji, Eigo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Akt; c Met; CT26; Erk1 2; HGF; NK4; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CISPLATIN; CYTOKINE RECEPTOR ANTAGONIST; DOCETAXEL; FLUOROURACIL; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NK4 PROTEIN; PROTEIN KINASE B; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CELL PROLIFERATION; COLON ADENOCARCINOMA; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION REGULATION; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CISPLATIN; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; CRICETINAE; CRICETULUS; FEMALE; FLUOROURACIL; GENE EXPRESSION; GENE THERAPY; HEPATOCYTE GROWTH FACTOR; MICE; MICE, INBRED BALB C; PROTO-ONCOGENE PROTEINS C-MET; RNA, MESSENGER; TAXOIDS; THYMIDYLATE SYNTHASE;

EID: 79960449048     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K and Shimizu S: Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440-443, 1989.
2. Miyazawa K, Tsubouchi H, Naka D, Takahashi K, Okigaki M, Arakaki N, Nakayama H, Hirono S, Sakiyama O and Takahashi K: Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun 163: 967-973, 1989. (Pubitemid 19236944)
3. Birchmeier C, Birchmeier W, Gherardi E, and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925, 2003. (Pubitemid 37493640)
4. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, and Nakamura T: Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 53: 35-69, 2005. (Pubitemid 39656109)
5. Fukuura T, Miki C, Inoue T, Matsumoto K and Suzuki H: Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma. Br J Cancer 78: 454-459, 2005.
6. Osada S, Matsui S, Komori S, Yamada J, Sanada Y, Ihawa A, Tanaka Y, Tokuyama Y, Okumura N, Nonaka K, Hosono Y, Takahashi T, Yamaguchi K and Yoshida K: Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterology 57: 76-80, 2010.
7. Hiscox SE, Hallett MB, Puntis MC, Nakamura T and Jiang WG: Expression of the HGF/SF receptor, c-MET, and its ligand in human colorectal cancers. Cancer Invest 15: 513-521, 1997. (Pubitemid 28015594)
8. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, Nordlinger B, Bretti S, Bottardi S, Giordano S, Plebani M, Gespach C and Comoglio PM: Overexpression and amplification of the METIHGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1: 147-154, 1995.
9. Umeki K, ShiotaG and Kawasaki H: Clinical significance of c-MET oncogene alterations in human colorectal cancer. Oncology 56: 314-321, 1999.
10. Date K, Matsumoto K, Shimura H, Tanaka M and Nakamura T: HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 420: 1-6, 1997. (Pubitemid 28037188)
11. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M and Nakamura T: HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60: 6737-6743, 2000.
12. Bowers DC, Fan S, Walter KA, Abounadar R, Williams JA, Rosen EM and Lattera J: Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 60: 4277-4283, 2000.
13. Lasagna N, Fantappiè O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M and Mazzanti R: Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res 66: 2673-2682, 2006.
14. Kubota T, Fujiwara H, Amaike H, Takashima K, Inada S, Atsuji K, Yoshimura M, Matsumoto K, Nakamura T and Yamagishi H: Reduced HGF expression in subcutaneous CT26 tumor genetically modified to secrete NK4 and its possible relation with antitumor effects. Cancer Sci 95: 321-327, 2004. (Pubitemid 38519472)
15. Seki T, Ihara I, Sugimura A, Shimonishi M, Nishizawa T, Asami O, Hagiya M, Nakamura T and Shimizu S: Isolation and expression of cDNA for different forms of hepatocyte growth factor from human leukocyte. Biochem Biophys Res Commun 172: 321-327, 1990. (Pubitemid 20352539)
16. Gavrieli Y, Sherman Y and Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1992.
17. Carbonari M, Cibati M and Fiorilli M: Measurement of apoptotic cells in peripheral blood. Cytometry 22: 161-167, 1995.
18. 2 arrest and apoptosis in keloid fibroblasts. Br J Dermatol 163: 1181-1185, 2010.
19. 2 phase arrest in human breast cancer grafted in nude mice. Anticancer Res 16: 2699-2704, 1996.
20. Kang MH, Kang HN, Kim JL, Kim JS, Oh SC and Yoo YA: Inhibition of PI3 kinase/Akt pathway is required for BMP2-induced EMT and invasion. Oncol Rep 22: 525-534, 2009.
21. Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM, Morrow JD and Capdevila JH: Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 279: 29797-29804, 2004. (Pubitemid 38915863)
22. Yoshimura M, Fujiwara H, Kubota T, Amaike H, Takashima K, Inada S, Atsuji K, Araki Y, Matsumoto K, Nakamura T and Yamagishi H: Possible inhibition of cancer cell adhesion to the extracellular matrix in NK4-induced suppression of peritoneal implantation. Anticancer Res 25: 3847-3854, 2005. (Pubitemid 41665154)
23. Kubota T, Taiyoh H, Matsumura A, Murayama Y, Ichikawa D, Okamoto K, Fujiwara H, Ikoma H, Nakanishi M, Kikuchi S, Sakakura C, Ochiai T, Kokuba Y, Taniguchi H, Sonoyama T, Matsumoto K, Nakamura T and Otsuji E: NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells. Clin Exp Metastasis 26: 447-456, 2009.
24. Maehara N, Matsumoto K, Kuba K, Mizumoto K, Tanaka M and Nakamura T: NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br J Cancer 84: 864-873, 2001. (Pubitemid 32275664)
25. Fujiwara H, Kubota T, Amaike H, Inada S, Takashima K, Atsuji K, Yoshimura M, Maemondo M, Narumi K, Nukiwa T, Matsumoto K, Nakamura T, Hagiwara A and Yamagishi H: Suppression of peritoneal implantation of gastric cancer cells by adenovirus vector-mediated NK4 expression. Cancer Gene Therapy 12: 206-216, 2005. (Pubitemid 40205101)
26. Jie J-Z, Wang J-W, Qu J-G, Wang W and Hung T: Effects of adenoviral-mediated gene transduction of NK4 on proliferation, movement, and invasion of human colonic LS174T cancer cells in vitro. World J Gastroenterol 12: 3983-3988, 2006. (Pubitemid 44097104)
27. Tomioka D, Maehara N, Kuba K, Mizumoto K, Tanaka M, Matsumoto K and Nakamura T: Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 61: 7518-7524, 2001. (Pubitemid 32995042)
28. Saimura M, Nagai E, Mizumoto K, Maehara N, Minamishima YA, Katano M, Matsumoto K, Nakamura T and Tanaka M: Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clin Cancer Res 8: 3243-3249, 2002. (Pubitemid 35155037)
29. Akao Y, Noguchi S, Iio A, Kojima K, Takagi T , and Naoe T: Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 300: 197-204, 2011.
30. Meng RD, Shelton CC, Shelton CC, Li YM, Qin LX, Notterman D, Paty PB and Schwartz GK: γ-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 69: 573-582, 2009.
31. Caraglia M, Marra M, Budillon A, Meo G, Ricciardiello F, Bismuto E, Brachelente G, Francini G, Giordano A, Correale P and Abbruzzese A: Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation. Cancer Biol Ther 4: 1159-1167, 2005. (Pubitemid 41598574)
32. Onimaru M, Ohuchida K, Egami T, Mizumoto K, Nagai E, Cui L, Toma H, Matsumoto K, Hashizume M and Tanaka M: Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells. Cancer Gene Ther 17: 541-549, 2010.
33. Egami T, Ohuchida K, Miyoshi K, Mizumoto K, Onimaru M, Toma H, Sato N, Matsumoto K and Tanaka M: Chemotherapeutic agents potentiate adenoviral gene therapy for pancreatic cancer. Cancer Sci 100: 722-729, 2009.
34. Namiki Y, Namiki T, Yoshida H, Date M, Yashiro M, Matsumoto K, Nakamura T, Yanagihara K, Tada N, Satoi J and Fujise K: Preclinical study of a tailor-made combination of NK4-expressing gene therapy and gefitinib (ZD 1839, Iressa) for disseminated peritoneal scirrhous gastric cancer. Int J Cancer 118: 1545-1555, 2006.